Drug intelligence / Profile preview

cephalexin + ciprofloxacin + metronidazole

Development stage: Unknown
Lead developer: Bayer
Modality: Small Molecules
Administration: Oral

Overview

This combination is not a standard or commonly prescribed formulation. Cephalexin is a cephalosporin antibiotic that inhibits bacterial cell wall synthesis. Ciprofloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA replication. Metronidazole is an antibiotic and antiprotozoal agent that damages DNA in anaerobic bacteria and protozoa, leading to cell death. Together, they could theoretically treat a wide range of bacterial infections, including those involving aerobic and anaerobic bacteria.

Targets

DNA gyrasePBP (Penicillin-binding protein family)Topo IV (Bacterial Topoisomerase IV)

Beyond the preview

Go deeper on cephalexin + ciprofloxacin + metronidazole.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cephalexin + ciprofloxacin + metronidazole.

Explore the full profile